Originally published In Press as doi:10.1074/jbc.M110637200 on March 23, 2002
J. Biol. Chem., Vol. 277, Issue 22, 19806-19810, May 31, 2002
The Molecular Basis of Src Kinase Specificity during Vertebrate
Mesoderm Formation*
Joanne
Hama
,
Crystal
Suri
,
Tomomi
Haremaki, and
Daniel C.
Weinstein§
From the Department of Pharmacology and Biological Chemistry, Mount
Sinai School of Medicine, New York, New York 10029
Received for publication, November 5, 2001, and in revised form, March 4, 2002
 |
ABSTRACT |
Members of the Src family of non-receptor
tyrosine kinases play a critical role in mesoderm formation in the
frog, Xenopus laevis, acting as required
mediators downstream of the fibroblast growth factor receptor.
At least four members of this gene family, Src, Fyn, Yes, and Laloo,
are expressed during early embryonic development. Ectopic expression of
Laloo and Fyn, but not Src, induce mesoderm in ectodermal explants,
indicating that these factors are non-redundant during early vertebrate
development. Here we investigate the basis for the differential
activity of the Src and Laloo kinases during mesoderm formation. We
demonstrate that although both Src and Laloo physically interact with
the substrate protein SNT-1/FRS2
only Laloo phosphorylates SNT-1, an
event previously shown to be required for the activity of the latter
and for mesoderm induction in vivo. We show that Src is enzymatically capable of stimulating mesoderm formation, as an activated Src construct both phosphorylates SNT-1 and induces mesoderm
in explant cultures. However, a chimeric Laloo construct containing a
Src C-terminal tail is inactive, suggesting that the early embryo
contains a specific Laloo-activating, or Src-inactivating, factor.
Finally, through further chimeric analysis, we provide evidence
to suggest that differences in Laloo and Src activity are also mediated
by the SH2, SH3, and kinase domains of these molecules.
 |
INTRODUCTION |
The mesodermal germ layer plays a fundamental role in organizing
the vertebrate body axes and gives rise to the skeletal, muscular, and
circulatory systems. In the frog, Xenopus laevis, members of both the transforming growth factor-
and fibroblast growth factor (FGF)1 ligand
families have been shown to play critical roles during mesoderm
formation (1). In recent years, a model has emerged in which members of
the Src family of non-receptor tyrosine kinases serve as central
mediators of the signal transduction cascade initiated by activation of
the FGF receptor. Both the Xenopus Src kinase Laloo and the
related Xenopus Fyn induce mesoderm in ectodermal (animal
cap) explants (2-4). Induction by these factors is blocked by reagents
that inhibit signaling downstream of the FGF receptor; conversely, Src
family kinase activity is required for mesoderm induction by FGF (3,
4).
The epistasis studies described above indicate that the Src kinases
function as required components of the cascade triggered by the FGF
receptor during mesoderm formation. The molecular interactions underlying this requirement have begun to emerge. A physical
association between Laloo and the FGF receptor-associated scaffolding
protein SNT-1/FRS2
has recently been demonstrated (5, 6). SNT-1 contains six tyrosine residues, which upon phosphorylation serve as
binding sites for both the Grb2 adaptor protein and the Shp2 phosphatase (7-9). An unphosphorylatable form of SNT-1 prevents mesoderm induction by FGF downstream of Laloo, suggesting that Laloo
functions to recruit Shp2 and Grb2 to SNT-1 by phosphorylation of SNT-1
(5, 6). The demonstration that an activated Laloo mutant can
phosphorylate exogenous SNT-1 supports such a role for endogenous Laloo
(5).
An initial challenge in elucidating the mechanism of Src kinase
function during mesoderm formation has been to determine which members
of this sizeable protein family are directly involved in mediating the
mesoderm-inducing signal. In addition to Laloo, the Src, Fyn, and Yes
kinases are also expressed during early Xenopus development
(2, 10, 11). Although Xenopus Fyn activity is
indistinguishable from that of Laloo, Xenopus Src, with a
primary sequence very similar to that of Fyn, is completely inactive in mesoderm induction assays (4).
We have attempted to dissect the molecular basis for differences in the
behavior of these related proteins, anticipating that such studies
would provide us with valuable insights on the mechanisms by which
these factors function during early development. Here, we demonstrate
that Src, like Laloo, physically associates with SNT-1; however,
although Laloo effectively phosphorylates tyrosine residues on SNT-1,
Src does not. We then demonstrate that SNT-1 may serve as a Src
substrate under some conditions, as an activated form of Src both
induces mesoderm and phosphorylates SNT-1. We provide evidence
suggesting that Src inactivity during early development is due to the
action of a factor that specifically recognizes the C-terminal tail of
Src but not a similar motif in Laloo. Finally, we demonstrate that the
SH3, SH2, and kinase domains of Laloo may additionally contribute to
differences in activity of the two molecules.
 |
EXPERIMENTAL PROCEDURES |
RNA Preparation, Explant Dissection, and Cell Culture--
RNA
was synthesized in vitro in the presence of the cap analog
using the mMessage mMachine kit (Ambion). Microinjection, explant dissection, and culture were performed as described (12, 13).
Preparation of Laloo, Src, and SNT-1 Constructs--
SNT-1-Myc
and Laloo-FLAG construction were described previously (6, 14). Src-FLAG
includes the sequence DYKDDDDK at the Src C terminus. SrcY526F was
generated by PCR-based mutagenesis (TAC
TTC) at nucleotide 1579 of
Xenopus Src. Domain-swap hybrids were constructed by PCR;
domains were defined as corresponding to the following amino acids
(Laloo accession number AAC31209; Xenopus Src accession
number AAA49962): Laloo SH4, 1-55; Laloo SH3, 56-117; Laloo
SH2, 118-232; Laloo kinase, 233-483; Laloo tail, 484-496; Src SH4,
1-85; Src SH3, 86-147; Src SH2, 148-255; Src kinase, 256-517; Src
tail, 518-532.
RT-PCR--
RT-PCR was performed as described (3, 13). All
primer sequences are as described (3, 12, 15).
Xenopus Co-immunoprecipitation Assay--
50 pg of SrcY526F and
1 ng each of Laloo-FLAG, Src-FLAG, and/or SNT-1-Myc RNA were injected
into the animal poles of early cleavage stage embryos. Embryos were
lysed after 6 h in 500 µl of lysis buffer (20 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40,
and 1 Complete minitablet/10 ml of buffer (Roche)). For studies
examining tyrosine phosphorylation of SNT-1, lysis buffer included 1 mM sodium orthovanadate. After 30 min of incubation on ice,
lysates were centrifuged twice, 2 min each at 4 °C at 14,000 × g; after each centrifugation, only the clear lysate was retained. Lysates were incubated overnight at 4 °C with
1:1000 antibody (anti-FLAG M2 monoclonal or anti-Myc tag monoclonal
9E10 (Sigma)), followed by incubation with protein A/G-PLUS-agarose (Santa Cruz Biotechnology) for 1 h at 4 °C. After four washes in lysis buffer, protein was eluted in 0.1 M glycine, pH
3.5, neutralized with wash buffer (0.05 M Tris, pH 7.4, 0.15 M NaCl), and subjected to standard SDS-PAGE and
Western blotting protocols.
 |
RESULTS |
Src Is Expressed but Inactive in the Mesoderm during
Gastrulation--
The expression patterns and activities of
Xenopus FGFs are consistent with a model in which FGF
pathway activation within the gastrula stage marginal zone is required
for the proper response to and maintenance of mesoderm induction.
Although both maternal and zygotic Xenopus src
transcripts have been identified (10, 15), the localization of
Xenopus src during gastrulation has not been
characterized. As shown in Fig.
1A, src is present
throughout the gastrula stage embryo, including in the cells of the
dorsal and ventral marginal zone (Fig. 1A). Thus,
Xenopus src, like laloo, is expressed
in the cells of the presumptive early mesoderm, consistent with a role
for these factors in mesoderm formation.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Xenopus Src is expressed in the
marginal zone but is inactive in gastrula-stage mesoderm.
A, RT-PCR analysis of Xenopus src
(Xsrc) expression in gastrula stage explants (stage 10.5).
B, RT-PCR analysis of animal caps dissected at late blastula
stages and cultured until midgastrula stages. Animal caps were isolated
from uninjected embryos or embryos injected with src RNA at
the two-cell stage as listed. 25 ng/ml (high) and 1 ng/ml
(low) bFGF were added as listed. The embryo-RT
lane contains all reagents except reverse transcriptase and
was used as a negative control. Ornithine decarboxylase
(ODC, Ref. 23) and EF1- (24) were used as loading
controls. Xbra is a panmesodermal marker at this stage (16).
Chordin is a dorsal mesodermal marker (25). Xwnt8
is a ventrolateral mesodermal marker (17, 18). RT-PCR data for Xbra,
Chordin, and Xwnt8 expression in A was derived previously
(6).
|
|
Although previous studies of Src function in mesoderm formation have
been performed by introducing src transcripts into competent ectoderm, it is conceivable that Src, unlike Laloo, requires a mesodermal context for activation. To address this possibility, we
examined Src activity in embryonic mesoderm. It was not possible to
assay for Src function directly in the marginal zone, the site of
endogenous mesoderm formation, because of the high levels of mesoderm-specific marker genes already expressed in these cells; this
strong baseline expression precluded detection of additional mesoderm
induction by ectopic Src. As an alternative approach, we examined
whether ectopic Src could boost mesoderm generated by low levels of the
mesoderm-inducing factor, basic FGF (bFGF). As shown in Fig.
1B, 25 ng/ml bFGF is a potent inducer of both the
panmesodermal marker Xbrachyury (Xbra) and the
ventrolateral mesodermal marker Xwnt8 (Fig. 1B,
lane 1; Refs. 16-18). 1 ng/ml bFGF induces low
levels of these markers (Fig. 1B, lane 2).
Expression of high doses of src mRNA does not induce
expression of these markers (Fig. 1B, lane 3;
Ref. 4); furthermore, Src expression does not enhance mesoderm
induction by 1 ng/ml bFGF (Fig. 1B, compare lanes
2 and 4). Thus, Src misexpression cannot stimulate mesoderm formation in either an ectodermal or a mesodermal context.
Src Interacts with the Laloo Kinase Substrate
SNT-1/FRS2
--
Laloo physically interacts with SNT-1 and
phosphorylates tyrosine residues on SNT-1 (5, 6). Because
phosphorylatable SNT-1 is required for mesoderm induction by Laloo
(5, 6), we examined whether Src inactivity in the mesoderm induction
assay could be due to an inability to bind SNT-1. Towards this end, we
expressed epitope-tagged SNT-1 with either tagged Laloo or Src in early
cleavage stage embryos and performed co-immunoprecipitation assays on
lysates from these embryos that were harvested at blastula stages. As
shown in Fig. 2, both Laloo and Src
physically associate with exogenous SNT-1 (Fig. 2, lanes 4 and 5). These results suggest both that endogenous Src
interacts with SNT-1 and that differences in SNT-1 affinity alone are
unlikely to underlie the difference in activity of these kinases during
mesoderm induction.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 2.
Src interacts with SNT-1. Western blot
analysis of SNT-1/Laloo and SNT-1/Src co-immunoprecipitation. Synthetic
RNA from epitope-tagged constructs was injected into early cleavage
stage embryos; 1 ng each of SNT-1-Myc, Laloo-FLAG, and Src-FLAG were
injected as listed. Cell lysates were collected at late blastula
stages. FLAG-tagged Laloo and/or Src protein was immunoprecipitated
using an anti-FLAG antibody. Co-precipitation of Myc-tagged SNT-1 was
detected by Western blot (top lanes). Expression of
epitope-tagged Laloo, Src, and SNT-1 protein was determined by Western
blot analysis of cell lysates (middle and bottom
lanes).
|
|
Src Does Not Phosphorylate SNT-1--
Studies using an activated
Laloo construct suggest that Laloo phosphorylates SNT-1 on one or more
of the tyrosine residues that serve as SHP2 and Grb2 binding sites (5).
As shown in Fig. 3, expression of
wild-type Laloo similarly triggers the tyrosine phosphorylation of
SNT-1 (Fig. 3, lane 3). Notably, however, ectopic expression
of Src does not induce any appreciable tyrosine phosphorylation of
exogenous SNT-1 (Fig. 3, lane 2). Because SNT-1 tyrosine
phosphorylation is required for mesoderm induction by Laloo and
in vivo, this result strongly suggests that Src fails to
induce mesoderm because it does not phosphorylate tyrosine residues on
SNT-1.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 3.
Laloo, but not Src, phosphorylates
SNT-1. Western blot analysis of SNT-1 immunoprecipitation.
Synthetic RNA from epitope-tagged constructs was injected into early
cleavage stage embryos; 1 ng each of SNT-1-Myc, Laloo-FLAG, and
Src-FLAG were injected as listed. Cell lysates were collected at late
blastula stages. Myc-tagged SNT-1 protein was immunoprecipitated using
an anti-Myc antibody. SNT-1 tyrosine phosphorylation was detected by
Western blot (top lanes). Expression of epitope-tagged
Laloo, Src, and SNT-1 proteins was determined by Western blot analysis
of cell lysates (middle and bottom lanes).
|
|
Role of the Src C-terminal Tail--
The inability of Src to
phosphorylate SNT-1 suggests that SNT-1 is an incompatible substrate
for Src and/or that Src activity is inhibited during mesoderm
formation. To distinguish between these possibilities, we constructed
an activated Src mutant. All Src family kinases contain a C-terminal
tyrosine residue that when phosphorylated significantly inhibits the
function of these proteins (19). We generated a
tyrosine-to-phenylalanine mutation in the corresponding residue
(Tyr-526) of Xenopus Src. mRNA synthesized from this
construct, SrcY526F, was first examined for its ability to induce
phosphorylation of SNT-1. In co-expression assays, SrcY526F consistently phosphorylated SNT-1 on tyrosine (Fig.
4A, lane 2). Levels
of SNT-1 phosphorylation were not as robust as that seen following
co-expression of SNT-1 and Laloo; this may be due to differences in the
levels of Laloo and SrcY526F protein expression.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of Src and Laloo by the Src C
terminus. A, Western blot analysis of SNT-1
immunoprecipitation. Synthetic RNA from epitope-tagged constructs was
injected into early cleavage stage embryos; 1 ng each of SNT-1-Myc and
SrcY526F were injected as listed. Cell lysates were collected at late
blastula stages. Myc-tagged SNT-1 protein was immunoprecipitated using
an anti-Myc antibody. SNT-1 tyrosine phosphorylation was detected by
Western blot (top lanes). Expression of SNT-1 protein was
determined by Western blot analysis of cell lysates (bottom
lanes). B and C, RT-PCR analysis of animal
caps dissected at late blastula stages and cultured until midgastrula
stages. 4 ng of src, 50 pg of SrcY526F, 1 ng of LST, and 1 ng of SLT
RNA were injected as listed. EF1- was used as a loading control.
Xbra is a panmesodermal marker. Chordin is a
dorsal mesodermal marker. Xwnt8 is a ventrolateral
mesodermal marker.
|
|
We next examined whether SrcY526F was active in the mesoderm induction
assay. As shown in Fig. 4B, injection of 50 pg of SrcY526F RNA is sufficient to induce both Xbra and Xwnt8
expression (Fig. 4B, lane 5); 4 ng of wild-type
src RNA, in contrast, produced no induction of either marker (Fig.
4B, compare lanes 1 and 5; Ref.
4). SrcY526F RNA is thus able to induce mesoderm at doses similar to those observed for activated Laloo (3).
In order to explore further the role of the Src C terminus in the
regulation of mesoderm formation, we generated Src-Laloo chimeric
molecules in which the C-terminal tails of the two proteins, including
the regulatory tyrosine residue, were exchanged. These reagents were
then tested for mesoderm-inducing activity in the animal cap assay. As
shown in Fig. 4C, both Laloo with the Src tail (lane
1, LST) and Src with the Laloo tail (lane
2, SLT) are inactive. This inactivity is not due solely
to the elimination of native sequence, because deletion of the tail
regions of either Src or Laloo produce activated molecules of
comparable potency to LalooY492F and SrcY526F (data not shown). Taken
together, these results demonstrate that the Src kinase is capable of
SNT-1 phosphorylation and mesoderm induction and suggest that the Src C
terminus inhibits Src activity in the early embryo.
Activity of Additional Src-Laloo Chimeras--
Although the
experiments described above indicate that the activated Src kinase can
induce mesoderm, the inactivity of SLT suggests that there may be other
regions of Laloo that preferentially activate the molecular cascade
that ultimately results in mesoderm formation. To examine this
possibility, we generated additional chimeric molecules in which the
SH4, SH3, SH2, and kinase domains of Laloo and Src were individually
exchanged. mRNA derived from these constructs were then tested in
the mesoderm induction assay. As shown in Fig.
5, exchange of the SH4 domains of Laloo
and Src had no effect; i.e. Laloo with the Src SH4 (Fig.
5A, lane 2, S4L) domain remained
active, and Src with the Laloo SH4 (Fig. 5A, lane 1, L4S) domain remained inactive. However, Src chimeras
that contain either the Laloo SH3 (Fig. 5B, lane
2, S(L3)S); SH2 (Fig. 5C, lane 2,
S(L2)S); or kinase (Fig. 5D, lane 2,
S(LK)S) domains induced the expression of both
Xbra and Xwnt8 at doses similar to those required
for wild-type Laloo. Laloo chimeras with the Src SH3 (Fig.
5B, lane 1, L(S3)L); SH2 (Fig.
5C, lane 1, L(S2)L); or kinase (Fig. 5D, lane 1, L(SK)L)
domains remained active. These data, summarized in Fig. 5E,
indicate that the Laloo SH3, SH2, and kinase domains are independently
sufficient to activate Src in the mesoderm induction assay but are not
specifically necessary for Laloo activity.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
Activity of Laloo-Src domain-swap
hybrids. A-D, RT-PCR analysis of animal caps dissected
at late blastula stages and cultured until midgastrula stages. 1 ng
each of L4S, S4L, L(S3)L, S(L3)S, L(S2)L, S(L2)S, L(SK)L, and S(LK)S
RNA were injected as listed. E, summary of Laloo-Src
chimeric experiments described in this study. Laloo domains are
boxes. Src domains are ovals. A positive score
for mesoderm-inducing activity was defined as stimulation of both
Xbra and Xwnt8 expression in gastrula stage
animal cap explants.
|
|
Regulation of Src-Laloo Chimeras--
The chimeric analyses
described above suggest important roles for multiple Src homology
domains during Src kinase-mediated mesoderm induction. It remains
possible, however, that the Src-Laloo chimeras are regulated
differently and/or induce mesoderm via molecular mechanisms distinct
from those that govern, or are governed by, the endogenous Src kinases.
Such a possibility complicates the interpretation of these data. To
address these issues, we next examined the upstream regulation of the
Src-Laloo domain-swap mutants. We decided to focus on those Src
constructs containing an activating Laloo region, because these display
a striking alteration of function mediated solely by the exchange of a
single functional domain. Thus, they are the constructs for which it is
most critical to determine faithful intracellular regulation.
We have previously demonstrated that mesoderm induction by the
Src-related kinases is inhibited by co-expression of a dominant inhibitory FGF receptor construct (XFD) (3, 4, 20). However, a
constitutively active Laloo mutant in which the C-terminal regulatory tyrosine is mutated to phenlyalanine (Y492F) is insensitive to FGF
receptor blockade, suggesting that signals downstream of the receptor
dephosphorylate the C-terminal tyrosine residue and activate wild-type
Laloo (3). As shown in Fig. 6, inhibition
of FGF receptor signaling significantly inhibits mesoderm induction by the domain-swap mutants S(L3)S (compare lanes 1 and
2), S(LK)S (compare lanes 3 and 4),
and S(L2)S (compare lanes 5 and 6). These data
suggest that the chimeric molecules are not constitutively active and
are regulated in a manner similar to that of Laloo.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of Src-Laloo domain-swap hybrids
by a dominant negative FGF receptor
construct. RT-PCR analysis of animal caps dissected at late
blastula stages and cultured until midgastrula stages. 1 ng each of
S(L3)S, S(L2)S, and S(LK)S RNA, and 2 ng of a truncated FGF receptor
construct (XFD, Ref. 20) were injected as listed. EF1-
was used as a loading control. Xbra is a panmesodermal
marker. Chordin is a dorsal mesodermal marker.
Xwnt8 is a ventrolateral mesodermal marker.
|
|
We next examined the molecular targets of the activated domain-swap
mutants. We have shown that Laloo, but not Src, phosphorylates tyrosine
residues on SNT-1 and that SNT-1 mutants lacking tyrosine phosphorylation sites block mesoderm induction by the Src kinases (Fig.
3 and Ref. 6). These data strongly suggest that the Src-related proteins induce mesoderm via the phosphorylation of SNT. In Fig. 7, we demonstrate that the activated Src
domain-swap constructs S(L3)S (lane 3), S(LK)S (lane
5), and S(L2)S (lane 6), like Laloo (lane 1)
but unlike Src (lane 2), phosphorylate SNT-1. Furthermore, mesoderm induction by these chimeric proteins is inhibited by co-expression of 6YF, an unphosphorylatable form of SNT-1 (data not
shown). These results suggest that the activated domain-swap constructs
used in this study induce mesoderm through the phosphorylation of
SNT-1, in a manner similar to that of wild-type Laloo.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 7.
SNT-1 phosphorylation by activated Src-Laloo
domain-swap hybrids. Western blot analysis of SNT-1
immunoprecipitation. Synthetic RNA from epitope-tagged constructs was
injected into early cleavage stage embryos; 1 ng each of SNT-1-Myc,
Laloo, Src, S(L3)S, S(LK)S, and S(L2)S RNA were injected as listed.
Cell lysates were collected at late blastula stages. Myc-tagged SNT-1
protein was immunoprecipitated using an anti-Myc antibody. SNT-1
tyrosine phosphorylation was detected by Western blot (top
lanes). Expression of Myc-tagged SNT-1 protein was determined by
Western blot analysis of cell lysates (bottom lanes).
|
|
 |
DISCUSSION |
Members of the Src kinase family play an essential role in
vertebrate mesoderm formation, functioning as mediators of a signaling cascade triggered by FGF receptor activation. Here, we have examined the basis for the differences in activity between the Src and Laloo
kinases during mesoderm induction. We have shown that Src inactivity is
likely a result of its inability to phosphorylate SNT-1 on tyrosine, an
event that is required for mesoderm formation in vivo.
Furthermore, our studies suggest that Src inactivity is mediated by the
phosphorylation state of a C-terminal tyrosine residue and that this
repression can be transposed to Laloo by exchange of a 15-residue
region. Finally, we have demonstrated that the SH3, SH2, and kinase
domains of Laloo may all confer additional specificity to this kinase
during early development.
The observation that activated Src behaves biochemically and
embryologically like Laloo suggests that Src inactivity during mesoderm
formation may be due in part to repression of Src via Tyr-526. Such
repression might be mediated by an inhibitory kinase that binds
specifically to the C terminus of Src or by an activating phosphatase
that binds preferentially to the Laloo C terminus. Although the
C-terminal Src kinase (Csk) appears to inhibit both Laloo and Fyn and
is thus not a good candidate for a Src-specific inhibitor, related
kinases may be present in the early Xenopus embryo that
fulfill this function (14). The SHP2 phosphatase is required for
FGF-mediated mesoderm induction (21). Although SHP2 activity is
required downstream of or in parallel to Laloo, the available data do
not preclude additional involvement of SHP2 upstream of Laloo (4);
thus, SHP2 may function as a preferential activator of a subset of Src
family proteins, including Laloo.
Negative regulation of the Src kinases is mediated by a number of
intramolecular interactions involving the SH3, SH2, and C-terminal
domains of these molecules (22). The activity of our Laloo-Src chimeras
thus likely reflects alterations in both intra- and intermolecular
stability. LST may be inactive in part because the phosphorylated Src
tail binds with more affinity than the Laloo tail to the Laloo SH2
domain. However, because activated Src but not SLT induces mesoderm,
the Src SH2 appears to bind both the Laloo and Src tails with
sufficient affinity to inhibit kinase function in these constructs.
Further complicating such a scenario, L(S2)L is active, suggesting that
SLT inactivity is not only due to interactions between the Src SH2
domain and the Laloo tail. When considered in aggregate, our results
point to the contribution of inter- as well as intramolecular
interactions underlying the differences in the ability of Src and Laloo
to participate in the activation of a mesoderm-forming signaling cascade. SNT-1 is a substrate of the Laloo kinase, and Laloo-SNT-1 association requires the Laloo SH3 domain in a yeast 2-hybrid assay
(this study and Refs. 5 and 6); thus, the differences we observe
between the SH3 and kinase domains of Laloo and Src may reflect the
differential ability of these molecules to bind and phosphorylate
SNT-1. These distinctions would not be manifest during mesoderm
formation in vivo, because C-terminal inhibition of Src
would block its capacity to phosphorylate SNT-1.
 |
ACKNOWLEDGEMENTS |
We thank Y. Song for excellent technical
assistance and P. Wilson for critical reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported by an Irma T. Hirschl Career
Scientist Award, by the Speaker's Fund for Biomedical Research: Toward the Science of Patient Care, awarded by the City of New York, by the
AMDeC (Academic Medicine Development Company) Foundation of New York
City, through its Tartikoff/Perelman/Entertainment Industry Fund for
Young Investigators in Women's Cancers, and by United States Public
Health Service Grant R01-GM61671 (all to D. C. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Members of the graduate training program in molecular, cellular,
biochemical, and developmental sciences.
§
To whom correspondence should be addressed: Dept. of
Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl., Box 1215, New York, NY 10029. Tel.:
212-659-1721; Fax: 212-831-0114; E-mail: weinsd01@doc.mssm.edu.
Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M110637200
 |
ABBREVIATIONS |
The abbreviations used are:
FGF, fibroblast growth factor;
bFGF, basic FGF;
Xbra, Xbrachyury;
SH, Src
homology;
L4S, Src with the Laloo SH4 domain;
S4L, Laloo with the Src
SH4 domain;
L(S3)L, Laloo with the Src SH3 domain;
S(L3)S, Src with the
Laloo SH3 domain;
L(S2)L, Laloo with the Src SH2 domain;
S(L2)S, Src
with the Laloo SH2 domain;
L(SK)L, Laloo with the Src kinase domain;
S(LK)S, Src with the Laloo kinase domain;
LST, Laloo with the Src tail;
SLT, Src with the Laloo tail;
RT, reverse transcriptase.
 |
REFERENCES |
| 1.
|
Klein, P. S.,
and Melton, D. A.
(1994)
Endocr. Rev.
15,
326-341[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Steele, R. E.,
Deng, J. C.,
Ghosn, C. R.,
and Fero, J. B.
(1990)
Oncogene
5,
369-376[Medline]
[Order article via Infotrieve]
|
| 3.
|
Weinstein, D. C.,
Marden, J.,
Carnevali, F.,
and Hemmati-Brivanlou, A.
(1998)
Nature
394,
904-908[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Weinstein, D. C.,
and Hemmati-Brivanlou, A.
(2001)
Dev. Dyn.
220,
163-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kusakabe, M.,
Masuyama, N.,
Hanafusa, H.,
and Nishida, E.
(2001)
EMBO Rep.
8,
727-735[CrossRef]
|
| 6.
|
Hama, J., Xu, H.,
Goldfarb, M.,
and Weinstein, D. C.
(2001)
Mech. Dev.
109,
195-204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kouhara, H.,
Hadari, Y. R.,
Spivak-Kroizman, T.,
Schilling, J.,
Bar-Sagi, D.,
Lax, I.,
and Schlessinger, J.
(1997)
Cell
89,
693-702[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Hadari, Y. R.,
Kouhara, H.,
Lax, I.,
and Schlessinger, J.
(1998)
Mol. Cell. Biol.
18,
3966-3973[Abstract/Free Full Text]
|
| 9.
|
Xu, H.,
and Goldfarb, M.
(2001)
J. Biol. Chem.
276,
13049-13056[Abstract/Free Full Text]
|
| 10.
|
Steele, R. E.
(1985)
Nucleic Acids Res.
13,
1747-1761[Abstract/Free Full Text]
|
| 11.
|
Steele, R. E.,
Irwin, M. Y.,
Knudsen, C. L.,
Collett, J. W.,
and Fero, J. B.
(1989)
Oncogene Res.
1,
223-233
|
| 12.
|
Hemmati-Brivanlou, A.,
and Melton, D. A.
(1994)
Cell
77,
273-281[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Wilson, P. A.,
and Hemmati-Brivanlou, A.
(1995)
Nature
376,
331-333[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Song, Y.,
Cohler, A. N.,
and Weinstein, D. C.
(2001)
Oncogene
20,
5210-5214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Weinstein, D. C.,
Honore, E.,
and Hemmati-Brivanlou, A.
(2001)
Development
124,
4235-4242[Abstract]
|
| 16.
|
Smith, J. C.,
Price, B. M. J.,
Green, J. B. A.,
Weigel, D.,
and Herrmann, B. G.
(1991)
Cell
67,
79-87[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Smith, W. C.,
and Harland, R. M.
(1991)
Cell
67,
753-765[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Christian, J. L.,
McMahon, J. A.,
McMahon, A. P.,
and Moon, R. T.
(1991)
Development
111,
1045-1055[Abstract/Free Full Text]
|
| 19.
|
Brown, M., T.,
and Cooper, J., A.
(1996)
Biochim. Biophys. Acta
1287,
121-149[Medline]
[Order article via Infotrieve]
|
| 20.
|
Amaya, E.,
Musci, T. J.,
and Kirschner, M. W.
(1991)
Cell
66,
257-270[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Tang, T. L.,
Freeman, Jr., R. M.,
O'Reilly, A. M.,
Neel, B. G.,
and Sokol, S. Y.
(1995)
Cell
80,
473-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Superti-Furga, G.
(1995)
FEBS Lett.
369,
62-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Bassez, T.,
Paris, J.,
Omilli, F.,
Dorel, C.,
and Osborne, H. B.
(1990)
Development
110,
955-962[Abstract/Free Full Text]
|
| 24.
|
Krieg, P.,
Varnum, S.,
Wormington, M.,
and Melton, D. A.
(1989)
Dev. Biol.
133,
93-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Sasai, Y., Lu, B.,
Steinbeisser, H.,
Geissert, D.,
Gont, L. K.,
and DeRobertis, E. M.
(1994)
Cell
79,
779-790[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Haremaki, S. T. Fraser, Y.-M. Kuo, M. H. Baron, and D. C. Weinstein
Vertebrate Ctr1 coordinates morphogenesis and progenitor cell fate and regulates embryonic stem cell differentiation
PNAS,
July 17, 2007;
104(29):
12029 - 12034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Ridyard and S. M. Robbins
Fibroblast Growth Factor-2-induced Signaling through Lipid Raft-associated Fibroblast Growth Factor Receptor Substrate 2 (FRS2)
J. Biol. Chem.,
April 11, 2003;
278(16):
13803 - 13809.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.